AnaptysBio (ANAB) Corporate presentation summary

Financial performance and revenue streams

• Jemperli generated $644 million in global net sales for the first half of 2026, up 34% year-over-year.

• Royalties from Jemperli are projected to exceed $390 million annually at GSK's peak sales guidance of over $2.7 billion.

• Cash and investments stood at $164.1 million as of June 30, 2026.

• Operating with fewer than 10 FTEs and annualized OpEx under $10 million, with anticipated EBIT margin above 95%.

• Receivables from Jemperli are subject to a capped non-recourse debt arrangement with Sagard, with $301 million accrued and $299 million remaining to be paid down by March 2031.

Product pipeline and clinical milestones

• Jemperli is approved or in development for multiple indications, including endometrial, colorectal, and head & neck cancers.

• Multiple high-value Jemperli trial readouts are expected through 2028, with key oncology conference presentations planned.

• Imsidolimab (Quimilza) is out-licensed to Vanda, with two positive Phase 3 studies in GPP and a BLA accepted by the FDA; target action date is December 12, 2026.

• Orphan designation for imsidolimab in the EU, with IP protection potentially extending to 2042.

Strategic partnerships and litigation

• Financial collaborations with GSK and Vanda provide significant and growing royalty streams.

• Jemperli royalties range from 8% to 25% of net sales, with patent protection in major markets through at least 2035.

• Ongoing litigation with GSK and Tesaro in Delaware Chancery Court, with a judgement anticipated in Q4 2026 or Q1 2027; seeking reversion of Jemperli rights.